Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, 200072, China
Location status: Recruiting
Recruiting
NCT Number: NCT03005132
Integrative Analysis of Human Glioblastoma Multiforme
Integrative analysis of GBM
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
The investigators will analyzed proteomes of paired normal brain tissues and GBM, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal brain tissue, primary GBM carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of GBM characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age ≤ 75 years with histologically proven GBM
- No severe major organ dysfunction
- World Health Organization (WHO) performance status of 0 or 1
- No prior cancer chemotherapy
Exclusion criteria
- Age ≥ 76
- Severe major organ dysfunction
- WHO performance status of >1
- Prior cancer chemotherapy
Treatment and study plan
Normal brain tissue
OtherThe investigators will extract total protein, DNA and RNA from the samples.
Primary outcomes
-
5 years overall survival
Time frame: 5 years
Secondary outcomes
-
5 years disease-free survival
Time frame: 5 years
-
10 years overall survival
Time frame: 10 years
-
10 years disease-free survival
Time frame: 10 years
Study contacts
Contact information is provided by the study sponsor or research team.
Da Fu, PhD
CONTACT
Yushui Ma, BS
CONTACT
Sponsors and collaborators
Lead sponsor
Shanghai 10th People's Hospital
Other
Collaborators
- Ganzhou City People's Hospital
- Jilin University
Registry information
Important dates
- Study start
- 2016
- Primary completion
- 2026
- Study completion
- 2026
- First posted
- Dec 29, 2016
- Registry last updated
- Dec 29, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
NCT07416188
Astrocytoma, Brain Cancer
Bethesda, Maryland, United States
View Trial Details
Recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169
Astrocytoma, GBM
Phoenix, Arizona, United States
View Trial Details
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566
Astrocytoma, Brain Cancer
Birmingham, Alabama, United States
View Trial Details
Recruiting
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
NCT07225621
Astrocytoma, GBM
Boston, Massachusetts, United States
View Trial Details